Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lek DD

Division of Novartis AG
www.lek.si

Latest From Lek DD

People Round-Up: Dipharma And Xellia North America Get New Heads

Dipharma appoints a new CEO, Xellia gets a new commercial head in North America, promotions are made at Lek, GVK Bio and the APhA, while appointments are seen at Auris Medical and Tris Pharma.

Appointments Strategy

Novartis/Hexal: Generic Consolidation, and More

Buying Hexal shows Novartis' commitment to generics. The Swiss group also hopes the move will bring more credibility, and better deals, across all of its businesses.
BioPharmaceutical Strategy

Savoring Sabex: Sandoz' Play in Injectable Generics

Sandoz, the generics unit of Novartis, is buying Sabex, a Canadian maker of injectable generics for $565 million cash, marking its entree into an attractive sector of generics and also the Canadian generics market. The 6X sales multiple aimed to dissuade Sabex owners from shopping for another buyer. Novartis is the only big pharma company to succeed in generics. Its play is opportunistic, but a secondary effect is a free-market response to pressure on big pharma to make drugs more affordable.
BioPharmaceutical

A Precarious Union: Combining Proprietary and Generic Businesses

The major generics companies, flush with cash from the recent plethora of patent expirations, are all forging ahead in the proprietary business in order to boost margins and even out the volatile revenues and earnings inherent in their core business. They're pursuing, by and large, strategies that don't take them far from their core expertise and involve reformulating known compounds. Some companies have had moderate success, but weaving together two such disparate businesses is a challenge.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Lek Pharmaceutical & Chemical Co.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Eastern Europe
        • Slovenia
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Metod Dragonja, CEO
  • Contact Info
  • Lek DD
    Phone: (386) 580 2111
    Verovskova 57
    Ljubljana, 1526
    Slovenia
Advertisement
Advertisement
UsernamePublicRestriction

Register